State Street Corp boosted its position in shares of Calithera Biosciences Inc (NASDAQ:CALA) by 5,802.1% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,304,375 shares of the biotechnology company’s stock after buying an additional 1,282,275 shares during the quarter. State Street Corp owned 3.68% of Calithera Biosciences worth $19,370,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. FMR LLC boosted its stake in shares of Calithera Biosciences by 85.8% during the second quarter. FMR LLC now owns 2,717,090 shares of the biotechnology company’s stock valued at $40,349,000 after purchasing an additional 1,254,900 shares during the period. Vanguard Group Inc. lifted its stake in Calithera Biosciences by 99.8% in the first quarter. Vanguard Group Inc. now owns 925,015 shares of the biotechnology company’s stock worth $10,684,000 after acquiring an additional 462,137 shares during the period. Northern Trust Corp lifted its stake in Calithera Biosciences by 1,355.1% in the second quarter. Northern Trust Corp now owns 337,640 shares of the biotechnology company’s stock worth $5,014,000 after acquiring an additional 314,436 shares during the period. Acadian Asset Management LLC lifted its stake in Calithera Biosciences by 608.7% in the second quarter. Acadian Asset Management LLC now owns 233,956 shares of the biotechnology company’s stock worth $3,474,000 after acquiring an additional 200,946 shares during the period. Finally, Artal Group S.A. purchased a new stake in Calithera Biosciences in the second quarter worth about $2,970,000. 72.19% of the stock is owned by institutional investors.
In related news, major shareholder Adage Capital Partners Gp, L.L sold 576,000 shares of the company’s stock in a transaction that occurred on Thursday, September 28th. The stock was sold at an average price of $15.64, for a total value of $9,008,640.00. The sale was disclosed in a document filed with the SEC, which is available at this link. 16.30% of the stock is owned by corporate insiders.
CALA has been the subject of a number of research reports. Zacks Investment Research raised shares of Calithera Biosciences from a “hold” rating to a “buy” rating and set a $19.00 price objective for the company in a research note on Monday, November 6th. William Blair started coverage on shares of Calithera Biosciences in a report on Thursday, October 5th. They issued an “outperform” rating for the company. BidaskClub upgraded shares of Calithera Biosciences from a “strong sell” rating to a “sell” rating in a report on Friday, August 18th. Finally, ValuEngine downgraded shares of Calithera Biosciences from a “hold” rating to a “sell” rating in a report on Friday. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $15.17.
Calithera Biosciences Inc (NASDAQ:CALA) traded down $0.60 on Monday, hitting $9.75. 564,972 shares of the stock traded hands, compared to its average volume of 745,145. Calithera Biosciences Inc has a 12-month low of $2.90 and a 12-month high of $20.05.
Calithera Biosciences (NASDAQ:CALA) last posted its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.23) by $0.06. The company had revenue of $7.20 million for the quarter, compared to analyst estimates of $6.02 million. sell-side analysts forecast that Calithera Biosciences Inc will post -0.77 EPS for the current year.
ILLEGAL ACTIVITY WARNING: This piece of content was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another website, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/12/04/state-street-corp-purchases-1282275-shares-of-calithera-biosciences-inc-cala.html.
Calithera Biosciences Profile
Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.
Receive News & Ratings for Calithera Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.